The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation

The extracted text does not present a formal methods section describing a systematic search strategy or explicit inclusion criteria. Instead, the paper is a narrative review combining published chemical, pharmacokinetic and electrophysiological studies with compilations of case reports and preclinical toxicology. The authors integrate their own experimental electrophysiology on heterologously expressed human cardiac ion channels (TSA-201 cell expression) and reference both published and some unpublished laboratory data (including studies on human induced pluripotent stem cell-derived ventricular-like cardiomyocytes and on noribogaine). The review draws on: animal pharmacology and toxicology reports; human pharmacokinetic measurements from clinical settings (notably work from a detoxification clinic group); in vitro ion-channel assays (hNav1.5, hCav1.2, hERG/hKv11.1 and Kv7.1); action potential recordings in isolated cardiomyocytes (guinea pig and, as stated, unpublished human iPSC-derived data); and a compilation of clinical case reports and post-mortem findings spanning earlier reviews and cases reported between 1990 and 2014. When specific experimental methods are referenced (e.g., channel expression systems, mutagenesis, docking), procedural detail is summarised rather than exhaustively described in the extracted text.

Chemistry and pharmacokinetics: Ibogaine and related iboga alkaloids share a tricyclic indole-based framework; noribogaine is the principal active metabolite formed mainly by CYP2D6-mediated O-demethylation. Typical oral doses used in addiction settings are 500–1000 mg (about 10–25 mg/kg). Plasma pharmacokinetics reported in humans show ibogaine Cmax around 1 µg/mL (total), with free plasma concentrations estimated at roughly 1–11 µM after accounting for ~65% protein binding; ibogaine half-life in plasma is approximately 4–7 hours. Noribogaine peaks around 2.5 hours and has a substantially longer plasma half-life (reported ~28–49 hours). 18-MC is primarily metabolised via CYP2C19 to 18-hydroxycoronaridine. Heart rate and haemodynamics: Animal studies and human monitoring indicate that ibogaine can slow heart rate. In a clinical monitoring series of 39 subjects receiving single 500–1000 mg doses, six developed significant bradycardia and one had significant hypotension. 18-MC produced little or no bradycardia or blood-pressure changes in animal experiments. Ion-channel and electrophysiological findings: Heterologous expression studies reported very low affinity of ibogaine and 18-MC for human cardiac sodium (hNav1.5) and L-type calcium (hCav1.2) channels at concentrations reached clinically: ibogaine IC50 for Nav1.5 ~142 µM (18-MC ~464 µM); hCav1.2 IC50 for ibogaine ~163 µM. In contrast, ibogaine inhibited hERG (hKv11.1) potassium channels with an IC50 of about 4 µM; 18-MC inhibited hERG with an IC50 of ~15 µM. Docking and mutagenesis studies localised the ibogaine binding pocket to the internal cavity involving S6 and selectivity-filter residues, with the drug targeting open and inactivated channel states. In guinea pig ventricular myocytes, high ibogaine concentrations shortened action potentials due to stronger calcium-channel inhibition in that species; however, the authors' unpublished data in human iPSC-derived ventricular-like cardiomyocytes indicate that low micromolar ibogaine prolongs the human ventricular action potential and flattens repolarisation. Noribogaine also inhibits hERG at low micromolar concentrations; one recent report cited an IC50 of ~3 µM for noribogaine. Clinical reports and fatalities: Preclinical dog testing and some supervised human studies under controlled conditions reportedly found no ECG abnormalities; nevertheless, between 1990 and 2008 nineteen fatalities temporally associated with ibogaine ingestion were compiled, six attributed to acute heart failure or cardiopulmonary arrest. Additional fatal cases were reported after 2008. Case-series data show that most decedents had pre-existing medical conditions or concomitant drug use; autopsies commonly documented cardiovascular comorbidities. Since 2008 eight cases of marked QT prolongation (QTc ranging from ~480 ms to over 700 ms) were reported; in most of these cases prolongation progressed to ventricular tachycardia, ventricular fibrillation and Torsade de pointes (TdP). The time to adverse events varied widely, from about 1.5 hours up to several days after ingestion, and QT prolongation has been observed to persist for more than 24 hours and sometimes over a week. Risk factors and modifiers: The authors emphasise recurrent findings of hypokalemia in fatal or near-fatal cases (potassium as low as 2 mM where tested) and hypomagnesemia in about half of those reports; both electrolyte abnormalities increase TdP risk and may potentiate hERG blockade. Polypharmacy is common among people receiving ibogaine: substances such as alcohol, cocaine and methadone, some of which prolong QT or inhibit CYP2D6, can magnify cardiotoxic risk. Genetic polymorphisms in CYP2D6 (5%-10% of Caucasians may lack enzyme function) lead to variable ibogaine/noribogaine exposure and complicate risk prediction. For 18-MC, lower hERG affinity suggests reduced cardiotoxicity relative to ibogaine, but reported IC50 values vary between studies and the absence of reliable plasma protein-binding data introduces uncertainty.

Koenig and colleagues interpret the assembled data as supporting a mechanistic link between ibogaine exposure and potentially life-threatening ventricular arrhythmias. They propose the following sequence: ibogaine (and noribogaine) block hERG potassium channels at clinically relevant free plasma concentrations, this reduces repolarising potassium current, prolongs the ventricular action potential and the QT interval, and creates a substrate for early after-depolarisations and TdP. The long plasma half-life of noribogaine offers a plausible explanation for prolonged QT abnormalities and delayed adverse events occurring days after a single dose. The authors place their electrophysiological findings in the context of prior preclinical and clinical observations, noting that earlier supervised studies sometimes failed to detect ECG changes whereas accumulating case reports document marked QT prolongation, ventricular arrhythmias and fatalities. They highlight the heterogeneity of the case reports: many decedents had cardiovascular comorbidities, electrolyte disturbances or concomitant drugs, and the QT correction method is often not stated, complicating interpretation. Key uncertainties recognised by the authors include incomplete characterisation of noribogaine metabolism, variable plasma protein binding (notably for 18-MC), reliance in part on unpublished laboratory data, and the limitations of passive case reporting which makes causal attribution and incidence estimation difficult. On practical implications, the authors recommend that ibogaine administration, if considered at all, be limited to medically supervised settings with continuous ECG monitoring over extended periods that account for noribogaine longevity. Pre-treatment screening should identify and exclude patients with risk factors for drug-induced TdP (female sex, baseline prolonged QT, bradycardia, electrolyte abnormalities, pre-existing cardiovascular disease, interacting drugs, known channelopathies, and relevant metabolic-genetic variants). They also underscore the need to characterise noribogaine metabolic pathways and to evaluate drug-drug interactions that could further increase cardiotoxic risk.

The authors conclude that ibogaine affects cardiac function in ways that can be life-threatening: it lowers heart rate and, at therapeutic concentrations, inhibits hERG potassium channels leading to action-potential and QT prolongation, with a consequent risk of TdP arrhythmias. Because noribogaine shares hERG inhibitory properties and has a much longer plasma half-life, it likely represents a principal contributor to prolonged cardiotoxic effects. Where clinical benefit may outweigh risk, ibogaine use should be confined to settings with strict medical observation, prolonged ECG surveillance, thorough screening for additional TdP risk factors, and informed consent that explains the risk of sudden cardiac death. The authors call for regulatory standards and exclusion criteria to improve safety, further research into noribogaine metabolism, and the development of ibogaine-like anti-addiction agents that retain efficacy but lack hERG affinity; they regard 18-MC as potentially less cardiotoxic but note remaining uncertainties.